Study of Intravenous TAD ® 600 mg/4 mL Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients With Pneumonia.

Conditions: Pneumonia; Myocardial Injury Interventions: Drug: TAD ® 600 mg/4 mL powder and solvent for solution for injection; Drug: Saline solution 0.9% of sodium chloride Sponsors: Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials